GSK484 是一种 PAD4 抑制剂,通过阻断 PAD4 催化活性有效抑制蛋白瓜氨酸化及胞外诱捕网 (NETs) 的形成,并可抑制组蛋白 H3 的生成、MHC-I 表达、CD8+ T 细胞活化、增殖及炎症细胞因子释放,同时能减轻胶原诱导性类风湿关节炎的炎症与骨破坏、缓解镰状细胞病的疼痛与肥大细胞活化、改善心肌缺血再灌注损伤和实验性结肠炎,还能通过逆转铁死亡诱导的菌群失调来恢复肠道微生物稳态,因此可用于研究类风湿关节炎、镰状细胞病、血栓、心肌损伤及结肠炎等疾病机制。
产品编号: MS-F77035 纯度: 99.14% CAS No.: 1652629-23-6 分子式: C27H31N5O3 分子量: 473.57
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

GSK484 是一种 PAD4 抑制剂,通过阻断 PAD4 催化活性有效抑制蛋白瓜氨酸化及胞外诱捕网 (NETs) 的形成,并可抑制组蛋白 H3 的生成、MHC-I 表达、CD8+ T 细胞活化、增殖及炎症细胞因子释放,同时能减轻胶原诱导性类风湿关节炎的炎症与骨破坏、缓解镰状细胞病的疼痛与肥大细胞活化、改善心肌缺血再灌注损伤和实验性结肠炎,还能通过逆转铁死亡诱导的菌群失调来恢复肠道微生物稳态,因此可用于研究类风湿关节炎、镰状细胞病、血栓、心肌损伤及结肠炎等疾病机制。

生物实验数据

生物活性 GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and extracellular trap (NETs) formation by blocking PAD4 catalytic activity, suppresses histone H3 generation, MHC-I expression, CD8+ T cell activation, proliferation, and inflammatory cytokine release, alleviates inflammation and bone destruction in collagen-induced rheumatoid arthritis, relieves pain and mast cell activation in sickle cell disease, ameliorates myocardial ischemia-reperfusion injury and experimental colitis, and restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis, and can therefore be used to study the mechanisms of diseases such as rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, and colitis.
体外研究
(In Vitro)

GSK484 (10 μM; 6 h) 可抑制 Erastin (MS-C46386) 诱导的人类类风湿关节炎成纤维样滑膜细胞中瓜氨酸化组蛋白 H3、HLA class I (MHC-I)、HLA-A2 的表达;在人类类风湿关节炎成纤维样滑膜细胞与 CD8+ T 细胞共培养体系中,的活化、增殖及炎症因子释放。
GSK484 抑制铁死亡上调的 PAD4 表达以及类风湿关节炎成纤维样滑膜细胞 (RA-FLS) 中相关的炎症反应。
GSK484 (10 μM) 可完全消除从纯合 BERK 镰状细胞 (HbSS) 小鼠背部皮肤分离的肥大细胞中由血红素/TNFα 诱导的巨细胞胞外诱捕网 (mast cell extracellular trap, MCET) 形成。
GSK484 (10 μM) 在缺氧前预孵育 2 小时的情况下,可在复氧 4 h 时维持原代培养的新生野生型小鼠心肌细胞的细胞内 ATP 水平,并在复氧 20 h 时改善其代谢活性;而在复氧开始时给药的情况下,仅能在复氧 20 h 时改善代谢活性,无法维持 ATP 水平。
GSK484 (10 μM; 15 min 预处理) 可强效抑制人中性粒细胞中由 Ionomycin (MS-F71073) 诱导 3 h 后的细胞外 DNA 产生及 H3Cit+ 中性粒细胞形成;但对 PMA (MS-C34076) 刺激或 SCD 患者分离的中性粒细胞无该效果。

ELISA Assay

Cell Line: Rheumatoid arthritifibroblast-like synoviocytes (RA-FLs)
Concentration: 10 μM
Incubation Time: 6 h; with or without the ferroptosis activator Erastin (MS-C46386) (0, 2.5, 5, or 7.5 μM) or the Fer-1 (MS-K98895) (0, 5, 10, or 15 μM) for 48 h
Result: Inhibited erastin-induced increase in HLA-I.
Inhibited erastin-induced T cell activation marker expression increase.
体内研究
(In Vivo)

GSK484 (10 mg/kg; i.p.; 每周 3 次; 共 6 次) 可抑制 Erastin (MS-C46386) 加重的 CIA 小鼠关节炎症、骨破坏、滑膜增生及炎症标志物表达,减轻该疾病模型中铁死亡增强带来的病理效应。
GSK484 (10 mg/kg; i.p.; 每周 3 次; 共 6 次) 可减轻 CIA 小鼠的关节炎症与骨破坏,逆转肠道菌群失调,使代谢谱恢复正常,并缓解 Erastin (MS-C46386) 诱导的 RA 相关病理恶化。
GSK484 (20 mg/kg; s.c.; 每日; 30 d) 可对纯合 BERK 镰状细胞小鼠产生持久的神经病理性痛觉过敏抑制作用,同时发挥广泛的抗炎及血液学益处,且无镇痛耐受现象。
GSK484 (10 μM; 单剂量; 血栓诱导前 30 分钟) 可在光激活血栓形成模型中显著延长 C57BL/6 小鼠脑小动脉和小静脉的血流停止时间,并显著增加镰状细胞转基因小鼠脑小动脉和小静脉的血流停止时间。
GSK484 (4 mg/kg; i.p.; 每 2 天 1 次; 9 d) 可显著降低 2% (w/v) DSS (MS-A45736) (36-50 kd) 诱导的结肠炎小鼠结肠黏膜 NET 密度,但无法改善临床或炎症疾病生物标志物。

Animal Model: DBA/1J mice with Rheumatoid arthritis (male, 8 weeks old, 21±2 g, SPF grade, collagen-induced arthritis model)
Dosage: 10 mg/kg
Administration: i.p.; three times a week; total of 6 times
Result: Inhibited erastin-exacerbated paw inflammation and reduced paw thickness compared to erastin-only treatment.
Inhibited erastin-exacerbated bone destruction, with micro-CT showing reduced joint damage relative to erastin-only treatment.
Reduced erastin-increased joint inflammation scores, bone erosion scores, and synovial hyperplasia scores via histological scoring.
Reduced erastin-increased MHC-I, citrullinated histone H3 (cit-h3), PAD4, CD8, TNF-α, and IFN-γ positive cell percentages in joint tissue via immunohistochemical analysis.
Animal Model: homozygous BERK sickle (HbSS) mcie with Sickle cell disease
Dosage: 20 mg/kg
Administration: s.c.; daily; 30 days
Result: Significantly reduced cold hyperalgesia at 48 hours.
Significantly reduced heat hyperalgesia at 72 hours.
Significantly reduced mechanical hyperalgesia after 1 week with attenuation persisting through 30 days and no analgesic tolerance observed.
Decreased skin mast cell degranulation by 90%.
Significantly reduced white blood cell counts.
Significantly reduced serum GM-CSF levels.
Significantly increased hematocrit.
Reduced skin levels of inflammatory cytokines CCL2/MCP-1, TNFα, and RANTES by approximately 50% relative to baseline/control groups.
Animal Model: Cerebrovascular thrombosis model in C57BL/6 mice (male and female, 8-10 weeks of age), Townes mice (male and female, 8-10 weeks of age, sickle transgenic)
Dosage: 10 μM
Administration: single dose (30 minutes prior to thrombosis induction)
Result: Significantly prolonged blood flow cessation time in both cerebrovascular arterioles and venules compared to vehicle-treated mice (C57BL/6).
Significantly increased blood flow cessation time in both cerebrovascular arterioles and venules compared to vehicle-treated mice (Townes), with a mean flow cessation time of ~28 minutes in arterioles and ~21 minutes in venules.
Animal Model: C57BL/6 mice with Inflammatory bowel disease (male, 7 weeks of age at study start, 2% w/v DSS-induced colitis)
Dosage: 4 mg/kg
Administration: i.p.; every second day; 9 days
Result: Significantly diminished colonic mucosal neutrophil extracellular trap (NET) density to levels similar to control mice.
Did not improve disease activity index scores, weight loss, colon length, colon weight/length ratio, fecal hemoglobin levels, or colonic/faecal calprotectin levels compared to DSS-only treated mice.
Did not reduce DSS-induced colon histoarchitectural damage, goblet cell loss, or mast cell density, nor alter levels of inflammatory cytokines IL-1β, IL-4, or IL-10.
Caused a statistically significant reduction in total superoxide dismutase (SOD) activity in colonic tissue.
Had no effect on catalase activity, Nrf2, GPx4, or SOD1 protein expression, or colonic lipid peroxidation.
性状 固体
颜色 White to off-white

化学信息

分子量 473.57
分子式 C27H31N5O3
CAS No. 1652629-23-6

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (105.58 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1116 mL10.5581 mL21.1162 mL52.7905 mL
5 mM0.4223 mL2.1116 mL4.2232 mL10.5581 mL
10 mM0.2112 mL1.0558 mL2.1116 mL5.2791 mL
15 mM0.1408 mL0.7039 mL1.4077 mL3.5194 mL
20 mM0.1056 mL0.5279 mL1.0558 mL2.6395 mL
25 mM0.0845 mL0.4223 mL0.8446 mL2.1116 mL
30 mM0.0704 mL0.3519 mL0.7039 mL1.7597 mL
40 mM0.0528 mL0.2640 mL0.5279 mL1.3198 mL
50 mM0.0422 mL0.2112 mL0.4223 mL1.0558 mL
60 mM0.0352 mL0.1760 mL0.3519 mL0.8798 mL
80 mM0.0264 mL0.1320 mL0.2640 mL0.6599 mL
100 mM0.0211 mL0.1056 mL0.2112 mL0.5279 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础